Weekly Vet Report: FDA clears feline hypertension drug, BOAS therapy advances: full analysis

This week’s veterinary news cycle brought together one immediately practice-changing approval and two early but potentially important research signals: FDA’s approval of Amodip for feline systemic hypertension, pilot data suggesting an injectable BOAS therapy may improve breathing in brachycephalic dogs, and a landmark feline cancer genomics paper that strengthens the case for cats as comparative oncology models. Of the three, the amlodipine approval is the most clinically actionable now. FDA announced the approval on April 29, 2026, calling Amodip the first FDA-approved amlodipine product for veterinary use and the second FDA-approved product for control of hypertension in cats. (fda.gov)

The feline hypertension news builds on a long-standing clinical reality: amlodipine has been widely used off-label as a first-line treatment for hypertensive cats, especially those with chronic kidney disease. Consensus guidance has already positioned amlodipine as a standard therapy in many cases, but until now U.S. veterinarians have largely relied on human-labeled formulations or compounding. FDA said the newly approved chewable tablet is given daily at a standard dose for the first 14 days, with dose escalation if response is inadequate, and emphasized ongoing blood pressure and laboratory monitoring. FDA also noted that cats weighing less than 2.5 kg can’t be accurately dosed with the product. (fda.gov)

That species-specific labeling matters because feline hypertension is often tied to chronic kidney disease and can quietly damage the eyes, kidneys, heart, and central nervous system if it goes untreated. FDA highlighted those target-organ risks directly in its approval notice, and recent feline comorbidity literature continues to underscore how often cardiovascular and renal disease intersect in older cats. In practical terms, an approved veterinary amlodipine may give clinicians a more standardized option for dosing, monitoring, and pet parent communication, even if it doesn’t change the underlying therapeutic strategy dramatically. (fda.gov)

The BOAS story is more preliminary, but it’s the kind of early-stage development that will get attention from clinicians managing high-risk brachycephalic patients. In a pilot study of six British bulldogs published in The Veterinary Journal, Snoretox-1 was associated with a reduction in BOAS severity by at least one grade, with reported benefit lasting from 20 to 53 weeks. RMIT University, which collaborated with Melbourne-based company Snoretox, said all six dogs in the early trial showed visible improvement and were better able to complete a brisk walk after treatment. The therapy uses a modified tetanus toxin designed to increase muscle tone in the floor of the mouth and help keep the airway open. (sciencedirect.com)

Researchers and company representatives are framing the injectable as a possible alternative or adjunct to surgery, not a replacement that’s ready for routine use. That distinction matters. The RMIT announcement said further research and regulatory approvals are still required, while also pointing to persistent unmet need in BOAS management. Tony Sasse, Snoretox’s managing director and an RMIT adjunct professor, said the team also observed improvement in dogs that had not responded well to previous surgery. The group is now planning a larger-scale trial. Because the current evidence comes from a tiny uncontrolled pilot and includes company-linked investigators, veterinary professionals should see this as intriguing proof-of-concept rather than established therapy. (rmit.edu.au)

The third item in the roundup, a feline cancer genomics study published in Science, is less about immediate case management and more about where comparative oncology may be headed. The international team sequenced 493 feline tumors spanning 13 cancer types from cats across five countries and found notable overlap between feline and human cancer drivers. Reporting on the paper, Cornell-linked researchers pointed to shared oncogenes and especially striking parallels between feline mammary tumors and some human breast cancer subtypes. The work supports a broader shift toward mutation-informed, cross-species oncology research, where naturally occurring disease in cats may help inform both veterinary and human cancer science. (phys.org)

Why it matters: For practicing veterinarians, the biggest takeaway is that one of these developments is ready for exam-room relevance now, while the others are signals to monitor. Amodip’s approval gives feline practitioners an FDA-approved amlodipine formulation at a time when hypertension screening in older cats, especially those with kidney disease or hyperthyroidism, remains clinically important. The BOAS injectable, if larger studies hold up, could eventually expand options for dogs that are poor surgical candidates or have residual disease after surgery. And the feline cancer atlas may gradually influence diagnostics, trial design, and how academic centers think about targeted therapies in cats. (fda.gov)

What to watch: Near term, expect attention on Amodip prescribing patterns and any practice-level education around blood pressure monitoring and follow-up; over the medium term, the key milestone for Snoretox-1 will be larger controlled studies and a clearer regulatory path; and for feline oncology, the next question is whether genomic discoveries begin translating into usable biomarkers, clinical trials, or targeted treatment decisions in referral settings. (fda.gov)